FREQ News and Press, Frequency Therapeutics Inc. From 03/15/22

Frequency Therapeutics press release (NASDAQ:FREQ): Q4 GAAP EPS of -$0.62 misses by $0.98. “The year ahead has numerous milestones for Frequency and our lead program FX-322, as we plan to complete enrollment and work toward a readout of our FX-322-208 Phase 2b study of individuals with...

Company Reports Steady Enrollment for FX-322-208 Phase 2b Study in Individuals with Sudden and Noise-Induced Sensorineural Hearing Loss; Topline Results Anticipated in Q4 2022 or Q1 2023 Continued Progress on Second Program for Hearing Restoration, FX-345; Phase 1b Start Antic...

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced that Chief Executive Officer David L. Lucchino will participate...

Company to Review Milestones for its Phase 2b Study of FX-322, the Near-Term Clinical Plan for its Second Hearing Restoration Asset, FX-345, and Selection of a Lead Candidate for its Novel Multiple Sclerosis Program that Has Shown Potent Pre-Clinical Data Frequency Therapeut...

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today shared the results from its FX-322-113 study, a placebo-controlled trial ...

Gainers: Stitch Fix  (NASDAQ:SFIX) +2%. Fate Therapeutics (NASDAQ:FATE) +2%. Frequency Therapeutics (NASDAQ:FREQ) +1%. Criteo  (NASDAQ:CRTO) +1%. EVgo  (NASDAQ:EVGO) +1%. Losers: Nexters  (NASDAQ:GDEV) -3%. Ocular Therapeutix (NASDAQ:OCUL) -2%. Sig...

Frequency Therapeutics (NASDAQ:FREQ): Q3 GAAP EPS of -$0.73. Cash and cash equivalents of $160.5M Press Release For further details see: Frequency Therapeutics reports Q3 results

Enrollment Underway for FX-322-208 Phase 2b Study in Subjects with Sudden and Noise-Induced Sensorineural Hearing Loss; Aligns with FDA on Speech Perception as Primary Endpoint for FX-322 Studies Expands Pipeline with New Pre-Clinical Program for Hearing Restoration that May P...

Management and Leading KOLs will Provide Detailed Review of Completed FX-322 Clinical Data in Subjects with Sensorineural Hearing Loss (SNHL), Supporting Design of FX-322-208 Phase 2b Study New Hearing Restoration Program Advances Toward Clinical Studies Providing Broader Coch...

At Nov. 9 Event, Management and Key Opinion Leaders to Review Detailed FX-322 Clinical Study Results in Patients with Sensorineural Hearing Loss (SNHL) and Design of New FX-322-208 Phase 2b Study Company to Introduce a Second Hearing Restoration Program with a Differentiated B...